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Abstract 
Background 
Drug repurposing or repositioning refers to the usage of existing drugs in diseases other than 
those it was originally used for. For diseases like malaria, where there is an urgent need for 
active drug candidates, the strategy offers a route to significantly shorten the traditional drug 
development pipelines. Preliminary high-throughput screens on patent expired drug libraries 
have recently been carried out for Plasmodium falciparum. This study reports the systematic 
and objective further interrogation of selected compounds reported in these studies, to enable 
their repositioning as novel stand-alone anti-malarials or as combinatorial partners. 
Methods 
SYBR Green flow cytometry and micro-titre plate assays optimized in the laboratory were 
used to monitor drug susceptibility of in vitro cultures of P. falciparum K1 parasite strains. 
Previously described fixed-ratio methods were adopted to investigate drug interactions. 
Results 
Emetine dihydrochloride hydrate, an anti-protozoal drug previously used for intestinal and 
tissue amoebiasis was shown to have potent inhibitory properties (IC50 doses of ~ 47nM) in 
the multidrug resistant K1 strain of P. falciparum. The sum 50% fractional inhibitory 
concentration (∑FIC50, 90) of the interaction of emetine dihydrochloride hydrate and 
dihydroartemisinin against the KI strains of P. falciparum ranged from 0.88-1.48. 
Conclusion 
The results warrant further investigation of emetine dihydrochloride hydrate as a potential 
stand-alone anti-malarial option. The interaction between the drug and the current front line 
dihydroartemisinin ranged from additive to mildly antagonistic in the fixed drug ratios tested. 
Keywords 
Drug repositioning, Antimalarial chemotherapy, Emetine, Dihydroartemisinin, Drug 
susceptibility assays, Flow cytometry 
Background 
The widespread emergence of anti-malarial drug resistance has rendered monotherapy 
regimes largely ineffective [1]. The World Health Organization recommendation for 
combination therapy with the use of artemisinins is aimed at impeding the development of 
resistance to the current frontline drug [2]. However, early resistance to artemisinins has been 
reported in the field and generated readily in the laboratory setting [3,4]. Furthermore, 
resistance to the majority of potential partner drugs available for artemisinin combination 
therapy (ACT) significantly limits combinatory options [5,6]. The urgent need to develop 
novel, potent anti-malarials as well as synergistic partners for artemisinins and ACT cannot 
be overemphasized. 
Reliance on the traditional drug development pathways to deliver on this goal would have 
significant implications on both cost and time. Drug repositioning or the screening of existing 
drugs for new uses, affords an attractive, alternate and valid paradigm for drug discovery 
[7,8]. Recent successes like the repositioning of Viagra® for erectile dysfunction and 
Thalidomide® for Erythema nodosum leprosum, have lead drug companies to explore 
repositioning on a more systematic basis [9,10]. Given that 90% of drug candidates fail 
during development, this approach which utilizes bioactive compounds with known safety 
profiles must necessarily be advantageous [11,12]. For diseases like malaria, drug 
repositioning may not only deliver novel candidates, but also provide partner drugs for 
combinatorial regimes with artemisinins, thereby increasing longevity of this highly effective 
and affordable frontline drug [13,14]. The void in the market for new anti-malarial drug 
classes and the lack of affordable alternatives in the developmental pipeline, make it 
imperative that faster drug developmental processes are urgently sought to avoid the 
imminent, potentially catastrophic consequences of drug failure. Patent expired drug 
compound libraries, such as the Library of Pharmaceutically Active Compounds (LOPAC: 
Sigma), have already been screened for anti-malarial activities and potential candidates 
identified [15]. This work and other screening initiatives have yielded a large compliment of 
anti-malarial drug candidates which are now available in the public domain in order to enable 
a more rigorous definition and characterization of their anti-malarial efficacies. Against a 
backdrop of emerging artemisinin resistance and a fast-depleting armamentarium of 
affordable anti-malarial therapeutic options, it is critical that candidates from such 
preliminary screening initiatives are further investigated objectively and systematically to 
evaluate their therapeutic potential. 
The work presented here follows on from data published from a high-throughput anti-
malarial screening initiative on three compound libraries, namely the Library of 
Pharmaceutically Active Compounds (LOPAC; Sigma), the library from the National 
Institute of Neurological Disorders and Stroke (NINDS) and the Library of uncharacterized 
compounds (Chembridge) [15]. The high-throughput 384-well luciferase screen on 12,320 
compounds at 5.5 µM concentrations yielded a total of 163 compounds exhibiting an 85% 
reduction in parasitaemia in the drug-sensitive 3D7 strain of P. falciparum. 
The objective of this study was the selective corroboration of some of the candidates 
identified in the Lucumi study and the further definition/characterization of these leads to 
identify stand-alone anti-malarial options and potential synergistic candidates for artemisinins 
[15]. This second phase screening was carried out on the multidrug resistant K1 strains of P. 
falciparum using a more robust drug susceptibility assay. SYBR green fluorescence-based 
micro titre plate and flow cytometric assays were optimized to map drug susceptibility. This 
versatile DNA-based screening technique is ideally suited for P. falciparum due to its 
location within an enucleate red blood cell and provides an objective and reliable method to 
study pharmacodynamics in an in depth manner. Emetine dihydrochloride hydrate was 
selected for further investigation of its anti-malarial properties based on the inferences from 
the preliminary screens of the LOPAC library. 
The significant advantages of combination therapy have been clearly demonstrated in recent 
clinical trials conducted in areas of drug-resistant malaria in Africa [16-18]. The preliminary 
work reported here provides a more in depth pharmacodynamic perspective of the anti-
malarial efficacy of emetine as a stand-alone anti-malarial and a combinatorial partner with 
dihydroartemisinin. The work justifies the further analysis of the anti-protozoan drug as a 
valid option for repurposing/repositioning in malaria. 
Methods 
Parasite culture 
Plasmodium falciparum parasites (strain K1) were maintained routinely in complete RPMI 
1640 medium containing L-glutamine (+) 25 mM Hepes (Gibco, Life Technologies, UK) 
supplemented with 5 mg/L albumin bovine serum fraction V (Sigma, UK), 50 mg/L 
hypoxanthine (Sigma, UK), 5 ml/L of 40% glucose (Dextrose Anhydrous, Fisher Scientific, 
UK) and 50 mg/L of gentamycin (Sigma, UK) in PBS. The parasites were constantly 
maintained in O + blood in accordance with the methods of Read and Hyde (1993) [19]. 
Whole blood was centrifuged at 3,000 rpm (4000 g) for 5 minutes at room temperature and 
the buffy coat removed. The process was repeated twice after re-suspension in 1640 RPMI to 
ensure complete removal of white blood cells. Washed blood was stored at 4°C as a 50% 
haematocrit in complete RPMI medium. Parasites were cultured continuously in 25 or 12.5 
cm2 flasks in final culture volumes of 10 ml and 5 ml respectively and maintained at 5% final 
haematocrit. Subcultures where completed at either 48 or 72 hour intervals. Sorbitol 
synchronization was carried out prior to experiments, as described previously [19,20]. 
Briefly, sorbitol solution (5% w/v in distilled water and filtered through a 0.22 µm filter) was 
added to the parasite pellet and incubated for 5 mins. The culture was centrifuged at 3,000 
rpm for 5 minutes and the supernatant discarded. The pellet was washed three times in 
complete RPMI prior to re-suspension at the appropriate haematocrit. Giemsa-stained thin 
blood smears were made to determine parasitaemia before sub-culture and prior to 
experimental set-ups. Cultures were initiated at a starting parasitaemia of 0.5%. Flasks were 
gassed with a 5% CO2, 5% O2, 90% N2 air mixture (BOC Limited, UK) and incubated in the 
dark at 37°C (Leec culture safe touch 190 CO2, Leec Limited, UK). 
Giemsa microscopic test 
A thin smear was prepared, air dried at room temperature and fixed in 100% methanol. The 
slide was stained for 20 min in Giemsa stain (BDH/WVR UK) diluted 1:10 in Giemsa buffer 
(BDH, UK). Parasitaemia was estimated by counting the percentage infected cells per field of 
view. For each slide, at least three fields of view were counted from which the average 
percentage of infected cells was calculated. 
Optimization of the SYBR green micro titre plate assay 
In order to optimize the SYBR Green micro-titre plate assay, fluorescence intensity reading 
was correlated with parasite density. In brief, spent media was removed from a continuous 
culture and the parasitaemia was determined by blood smear. The parasitized blood (50% 
haematocrit) was diluted with RPMI 1640 to either 10% or 5% haematocrit before transfer in 
duplicate (200 µl per well) to a 96 well plate. A non-infected blood sample (5% haematocrit) 
was also added in duplicate and served as a negative control. Two fold serial dilutions were 
then performed using 100 µl of RPMI 1640 leaving a final volume of 100 µl per well. 
Additional controls included wells containing 100 µl of either RPMI 1640 or complete media 
(6 wells per media solution). Finally, 100 µl of 2.5 x SYBR Green in RPMI 1640 was added 
to each well and the plate was incubated for 1 hour at room temperature (diluting starting 
haematocrits to 5% and 2.5% repectively). Fluorescence intensity was measured from above 
using a GENios plate reader (Tecan) with excitation and emmision wavelenghts of 485 nm 
and 535 nm respectively. Default settings of the Magellan software programme for 
em485/ex535 fluorescence were employed. Gain settings of the instrument were adjusted to a 
value of 80. Absolute fluorescence values for each well were recorded. There were dulplicate 
wells for each dilution and the experiment was repeated twice. 
Optimized SYBR green micro-titre plate assay for P. falciparum 
Following drug treatment, 5 ml of parasite culture was centrifuged at 14,000 g for 90 seconds 
and complete media replaced with an equivalent volume of RPMI 1640 to maintain a 5% 
haematocrit. A sample (100 µl) from each treatment flask was transferred to a 96 well plate 
(Nunc, Denmark) in triplicate. Controls included non-drug treated, infected and uninfected 
blood. SYBR Green1 nucleic acid gel stain (10,000 x, Sigma, UK) was diluted 2.5 x working 
solution in PBS and 100 µl added to each well, giving a total well volume of 200 µl and a 
final haematocrit of 2.5%. Following a one-hour incubation period at room temperature the 
plate was viewed immediately as described previously. The average absolute fluorescence 
values of triplicate wells for each condition were used to generate dose response curves. 
Three independent experiments were completed. 
SYBR green flow cytometry assay for P. falciparum 
Following the drug treatment procedure, 50 µl of a 5% haematocrit culture was transferred 
into fresh Eppendorf tubes. After a single washing step in PBS (centrifugation at 14,000 rpm 
for 90 secs) each pellet was re-suspended in I ml of 2.5 x SYBR Green1 solution and 
incubated in the dark for 20 mins at room temperature. Subsequently, the samples were 
centrifuged (14,000 rpm, 90 secs) and re-suspended in 250 µl of 0.37% formaldehyde 
solution in PBS (36% molecular biology grade, Sigma, UK). Following fixation, the samples 
were washed 3 x in PBS and re-suspended in 1 ml of PBS. Fifty thousand events were 
recorded for each sample using the FITC channel (Blue laser, excitation laser line 488 nm 
EXmax 494 nm/Emmax520nM) of the BD FACSVerse flow cytometer system. Scatter plots 
were automatically generated by the BDFACSuite software. FITC fluorescence was plotted 
against forward scatter and gating was conducted using standardized procedure. Percentage 
data was then obtained for fluorescent events (within the gates) relative to the total number of 
events recorded, and used to plot dose response curves. 
Preliminary drug screening for anti-malarial activity 
Five compounds, previously reported by Lucumi et al. [15] to be potent against P. falciparum 
strain 3D7 (IC50 ≤ 5 nM) were taken forward for preliminary screening against the drug 
resistant K1 strains. The compounds: Emetine dihydrochloride hydrate, SKF 95282 
dimaleate, S (−)-UH-301 hydrochloride, Vinblastine® and Vincristine® were selected from 
the Library of pharmaceutically active compounds (LOPAC: Sigma Aldrich). The LOPAC 
libraries were stored at −20°C in a 96 well plate format at a concentration of 1 mM. Working 
stocks were prepared by diluting 1:10 with DMSO, and test concentrations prepared by 
further dilution with RPMI 1640. Infected blood was diluted to ~ 0.5% parasitaemia and 
subdivided into 5 ml treatment flasks at 5% haematocrit. Parasites were then treated with the 
respective IC50 of each compound [15] and 10x the IC50 to account for the resistance 
phenotype of the K1 strain. LOPAC compounds were either administered alone or in 
combination with dihydroartemisinin (DHA). For the preliminary combination assays 
LOPAC compounds at IC50 were used with DHA 0.63 nM or 1.25 nM. The LOPAC 10x IC50 
treatments were co-administered with 0.63 nM DHA only to enable the combinatory effects 
to be monitored. Treated and control flasks were incubated under conditions described 
previously for 48 hours and analysed using the SYBR Green flow cytometer method. 
Drug preparation 
Dihydroartemisinin and emetine dihydrochloride hydrate were obtained from Sigma Aldrich. 
Stock solutions were prepared in DMSO at 5 mM, aliquoted and stored at −20°C. During 
parasite treatment the stock solution was serially diluted using RPMI to 5 µM. Appropriate 
volumes of the diluted stock solution were subsequently inoculated into 5 ml of parasite 
culture flasks to obtain the required test concentrations. Final test concentrations were within 
the 1 nM – 40 nM and 1 nM - 1000 nM range for DHA and emetine dihydrochloride hydrate 
respectively (Note: DMSO concentrations did not exceed 0.002%). 
In vitro drug interaction assay 
To investigate whether the combined effects of emetine hydrochloride hydrate were 
synergistic, additive or antagonistic, a previously described fixed ratio assay was employed 
[21]. Dihydroartemisinin and emetine dihydrochloride hydrate were combined in four fixed 
ratios 4:1, 3:2, 2:3 and 1:4. In addition, each drug was administered alone for direct 
comparison with the combinations, hereafter referred to as the 5:0 and 0:5 ratios. 
Approximately eight-fold IC50 values were used as 100% (8 x IC50 DHA = 20 nM and 8 x 
IC50 Eme = 400 nM). Thus for the first dilution the combinations were as follows for DHA 
(nM) : Eme (nM) 20:0, 16:80, 12:160, 8:240, 4:320 and 0:400 respectively. For each dilution 
thereafter drug concentrations were serially diluted two-fold. The IC50 for each compound (at 
the 5:0 and 0:5 ratios) therefore lay within the fourth dilution. Once drug stocks had been 
prepared in RPMI 1640, trophozoite stage parasites were diluted to ~0.5% parasitaemia and 
transferred into individual 5 ml treatment and control flasks at 5% haematocrit. Parasites 
were then treated with the various drug combinations, gassed (as described previously) and 
incubated for 48 hours at 37°C. Duplicate preparations were set up for each ratio at each 
dilution. Following treatment, samples were then analysed using the SYBR Green flow 
cytometry method. Giemsa staining of thin blood smears was also employed to permit 
parasite stage confirmation. 
In vitro stage specific effects of dihydroartemisinin and emetine 
dihydrochloride hydrate 
Parasites were treated with either IC50 DHA, IC50 emetine, or a combination of both 
compounds (IC50 DHA + IC50 Eme). Duplicate treatments were initiated at late trophozoite 
stage and carried out as described previously. Stage specific effects were analysed for 
untreated control cultures in parallel to drug treatments at 24, 48 and 72 hour time points. In 
brief, SYBR Green flow cytometry was used to differentiate between mononuclear and 
multinuclear parasite forms. The proportion of multinuclear cells was then displayed as a 
percentage of the total number of parasitized cells recorded for each treatment at each time 
point. 
Calculation of IC50 and IC90 values 
Data from the Giemsa, SYBR Green micro titre plate and SYBR Green flow cytometry 
assays were compared. For all data sets the infected blood controls were set at 100% and 
percentage parasitaemia for drug treated samples was calculated relative to the infected 
control. For IC50 and IC90 calculations data was further processed using Graphpad prism 5.0. 
Data was normalized so that the largest value in the data set corresponded to 100% and the 
smallest value corresponded 0%. Log-transformed drug concentrations were then plotted 
against the dose response and the IC50 and IC90 values were determined using non-linear 
regression (Graphpad prism 5.0). 
Results 
Lucumi et al. reported the high-throughput anti-malarial screening of 12,320 compounds 
from the LOPAC, NINDS and Chembridge libraries using a luciferase assay on the 3D7 
strain of P. falciparum [15]. Preliminary screens were carried out on drug resistant K1 strains 
of P. falciparum using two SYBR Green-based fluorescent assays. 
Optimization of the SYBR green micro titre plate assay 
The SYBR green method used here is a modification of methods published previously 
[22,23]. Due to the non-specific nature of the double-stranded DNA intercalation by the 
SYBR Green dye, stringent blood washing steps were introduced to ensure complete removal 
of the buffy coat containing nucleated white blood cells. The SYBR Green micro titre plate-
based assay was initially optimized using 2-fold serial dilutions of K1 parasite cultures at a 
haematocrit of 2.5 and 5% according to methods described above. Fluorescence intensities 
were measured on a GENios plate reader (Tecan) with excitation and emission wavelengths 
set at 485 nm and 535 nm respectively. Preliminary results with parasite cultures showed 
very poor reproducibility and little correlation between parasite density and fluorescence. 
Further method optimization identified the ‘complete’ RPMI medium from parasite cultures 
as being responsible for the variance in the results observed. The high background 
fluorescence was identified to the presence of Albumax® supplement in the complete media. 
RPMI media without Albumax showed minimal background fluorescence, and the 
introduction of a wash step with RPMI medium to remove the Albumax restored assay 
reliability and reproducibility (Figure 1). 
Figure 1 SYBR Green fluorescence intensity as a measure of parasite density. The SYBR 
Green fluorescence of parasitized blood at 5% or 2.5% haematocrit was measured at serial 2- 
fold dilutions in a 96 well micro titre plate assay. The correlation between parasite density 
and fluorescence intensity was determined. Controls included non-infected blood at 5% 
haematocrit, RPMI 1640 medium without Albumax and complete RMPI medium with 
Albumax. Error bars represent the standard error of two replicate experiments. 
Optimization of the SYBR green-based flow cytometry assay 
For the flow cytometric analysis, the gating strategy was adapted as previously described [24] 
and permitted the differentiation between mononuclear (ring and trophozoite) and 
multinuclear (schizont) parasite stages in unsynchronized K1 cultures (Figure 2). Accurate 
determination of percentage parasitaemia was achieved using the BDFACS Verse software 
programme. The dose response effect of dihydroartemisinin on synchronized K1, P. 
falciparum cultures initiated at ring stage, was compared between SYBR Green flow 
cytometric, micro titre plate and traditional Giemsa microscopic assays (Figure 3). IC50 
values for cultures sampled at 48 and 72 h post drug exposure were determined and compared 
using a one-way ANOVA (Graphpad prism). There were no significant differences between 
the three assays and although the IC50 values appear to be consistently higher at 72 hours than 
at the 48 hour time point for all three assays (Figure 3) this difference was not found to be 
significant. 
Figure 2 Comparison of parasitized and uninfected blood using the SYBR Green flow 
cytometric assay. Scatterplots from synchronised (a) uninfected and (b) infected cultures 
showing the gating strategy that enables the differentiation of mononuclear (ring/trophozoite) 
and multinuclear (schizont) parasite stages. 
Figure 3 Dose response curves for dihydroartemisinin against the K1 strain. A set of 
three parallel assays: namely, Giemsa microscopic test (Giemsa), SYBR Green microtitre 
plate assay (SG-Microplate) and the SYBR Green flow cytometer assay (SG-FCM). Cultures 
were initiated at ring stage and exposed to drugs for either 48 or 72 hrs. Each curve represents 
data from three independent experiments. 
Preliminary screening of selected compounds from the LOPAC library 
The LOPAC compound previously reported to have the highest anti-malarial potency (≤ 5 
nM against P. falciparum strain 3D7) were selected for further interrogation against the K1 
strain. An exemplar panel is shown in Figure 4. The nanomolar concentrations selected were 
based on preliminary IC50 values reported by Lucumi et al. [15], and 10-fold concentrations 
to accommodate variations due to the use of a drug resistant parasite strain. 
Dihydroartemisinin (DHA) controls, at 0.63, 1.25 and 2.5 nM, were included in the panel for 
comparison. A combination experiment was also carried out on the initial screen with DHA 
doses of 0.63 nM and 1.25 nM. Dose response experiments on the three drugs showed 
emetine to have the lowest IC50 value providing a rationale for further investigation. 
Figure 4 Preliminary screen of five LOPAC compounds with dihydroartemisinin. The 
LOPAC compounds Emetine dihydrochloride hydrate (EM), SKF 95282 dimaleate (SKF), S 
(−)-UH-301 hydrochloride (SUH), Vinblastine (VinB) and Vincristine (VinC) were either 
added alone or in combination with DHA for a 48 hr treatment period. All samples were 
analysed using the SYBR Green flow cytometric method. Parasitized blood and parasites 
treated with a range of DHA concentrations served as controls. Non-infected blood was also 
included and background fluorescence was deducted from all samples accordingly. 
Determination of dose response curves for emetine and dihydroartemisinin 
Emetine dihydrochloride hydrate was reported to have an IC50 value of 1 nM on the drug 
sensitive 3D7 P. falciparum parasite strains. Preliminary screening panels from our 
experiments showed effective parasite suppression for the drug, both alone and in 
combination with DHA. Dose response curves were determined for both drugs using K1 
resistant isolates and IC50 values of 47 ± 2.1 nM and 2.6 ± 0.41 nM established for emetine 
dihydrochloride hydrate and DHA, respectively (Figure 5). 
Figure 5 Representative dose response curves for dihydroartemisinin (a) and emetine 
(b). Parasites were treated at trophozoite stage and analysed at 48 hours using the SYBR 
Green flow cytometer method. IC50 values calculated from at least three independent 
experiments are also displayed. 
Isobologram preparation and data analysis 
Drug interaction studies for emetine dihydrochloride hydrate and DHA were performed using 
a modification of the fixed ratios method, employing 4 fixed ratios of 4:1, 3:2, 2:3 and 1:4. 
IC50 values were determined for each compound at each ratio as described above and used to 
calculate fractional inhibitory concentration for each ratio using the equation below. Drug 
interactions were analysed both at IC50 and IC90 values. 
Fraction of drug concentration required to produce IC50 when used in combinationFIC
Fraction of drug concentration required to produce IC50 when used alone
=  
 
The FIC values for DHA at each ratio were then plotted against those calculated for emetine 
and the isobologram trends obtained are shown in Figure 6. The convex shape of the IC50 
isobologram (Figure 6a) indicates an antagonistic interaction while the IC90 plot would 
suggest an additive interaction (Figure 6b). 
Figure 6 Isobolograms showing the interaction between dihydroartemisinin and 
emetine. The fixed ratio method was used to analyse the interaction between 
dihydroartemisinin and emetine dihydrochloride hydrate against trophozoite stage parasites. 
Treatments were set up in duplicate for 48 hours and analysed using the SYBR Green flow 
cytometer method. The FIC50 (a) and FIC90 (b) concentrations were determined and used to 
plot the isobologram. 
To investigate the interaction between DHA and emetine at each ratio the calculated FIC 
values for each compound were then added together to obtain the sum of the fractional 
inhibitory concentration (∑FIC) as per equation below. 
( ) IC50 of  A in mixture IC50of Bin mixtureSumFIC FIC +IC50of A alone IC50of Balone=∑   
The results from the fixed ratio experiment are presented in Table 1. 
Table 1 The interaction between dihydroartemisinin and emetine against P. falciparum 
(strain K1) at 6 fixed drug ratios 
Ratio Compound A 
(DHA) FIC50 
Compound A 
(DHA) FIC90 
Compound B 
(Eme) FIC50 
Compound B 
(Eme) FIC90 
∑FICs50, 
interaction 
∑FICs90, 
interaction 
5:0 1 1 0 0 n/a n/a 
4:1 0.914829 0.97142 0.412807 0.482675 1.327636, 1.454094 
3:2 0.638616 0.464741 0.837115 0.422492 1.475731 0.887233 
2:3 0.421106 0.310655 1.059061 0.71155 1.480167 1.022206 
1:4 0.238412 0.212022 1.167547 1.064742 1.405959 1.276764 
5.0 0 0 1 1 n/a n/a 
Individual FIC50 and FIC90 values for each ratio are displayed alongside respective ∑FIC 
values. 
All values represent an average of duplicate experiments. 
In vitro stage-specific effects of DHA and emetine dihydrochloride hydrate 
The results of the stage-specific analysis of DHA and emetine revealed variations in parasite 
progression pattern during the course of drug treatment. For DHA treated samples, progress 
into the multinucleated schizont form imitate that of the untreated control samples. However, 
emetine treated samples show a reversal of the pattern, representing a delay in parasite 
development. The combined effect of the drugs appears to display a true amalgamation of the 
two (Figure 7). It is also noteworthy that the overall parasitaemia of the combination is 
consistently lower throughout the course of drug than either of the individual component 
drugs. 
Figure 7 In vitro stage specific effects of dihydroartemisinin and emetine against P. 
falciparum. Trophozoite stage parasites were treated with IC50 DHA and IC50 emetine either 
alone or in combination for a 24, 48 and 72 hour time course. The percentage of multinuclear 
cells as a proportion of the total parasitaemia was recorded for each condition at each time 
point. The total parasitaemia is indicated by the numbers above bars. 
Discussion 
The objective and rigorous investigation of the large complement of anti-malarial drug 
candidates that have come through preliminary screening initiatives is a high priority. The 
second phase of inquiry must necessarily be more refined and objective, ideally providing a 
reliable quantitative indication of the early sub-cellular perturbations resulting from drug 
activity. 
The use of SYBR Green to monitor drug susceptibility exploits the fact that the parasites 
reside in red cells, which are devoid of a nucleus. A potential source of error would be the 
indiscriminate binding of SYBR Green to non-parasite DNA from white blood cells in the 
blood. However, the blood washing steps outlined in the methods section have helped to 
overcome this problem. Two SYBR Green fluorescence-based assays enabling the accurate 
and reproducible estimation of the effects of the drugs on the intracellular parasite stages 
were optimized. The higher throughput 96 well microtitre plate fluorescent assay tends to 
overestimate parasitaemia due to fluorescence from extra-erythrocytic parasite DNA. 
Optimizations achieved increased method reproducibility by identifying the very significant 
contribution of the albumax supplement from the parasite culture medium to variations in 
background fluorescence. The SYBR Green flow cytometry method uses a single tube format 
for analysis and offers a robust, albeit lower throughput route for the more in depth second 
phase inquiry of anti-malarial drug candidates selected from preliminary screens. 
Furthermore, stage-specific perturbations introduced by the drug could be accurately 
monitored. Hence in combination, the two methods described here would be valuable tools to 
screen and investigate the anti-malarial efficacy of compound libraries. 
Following on from the work of Lucumi et al. [15], five compounds were selected from 
preliminary screens carried out in, namely emetine dihydrochloride hydrate, SKF 95282 
dimaleate, S (−)-UH-301 hydrochloride, Vinblastine® and Vincristine®. A multi-drug 
resistant P. falciparum parasite line (K1) was used to derive preliminary dose response 
curves. Emetine dihydrochloride hydrate was taken forward for second phase investigation 
based on the dose response curves obtained. The drug exhibited potent anti-malarial 
properties at nanomolar concentrations (~47 nM) on the multi-drug resistant parasite line K1 
(1 nM in drug sensitive parasite lines [9]), justifying further investigation into its role as a 
stand-alone anti-malarial drug. 
Emetine dihydrochloride is an anti-protozoal drug derived from the root of Carapichea 
ipecacuanha (Ipecac®). The drug was previously used in the treatment of invasive intestinal 
amoebiasis and amoebic liver abscess [25]. Its use as a potent intestinal and tissue 
amoebicide was restricted due to side effects of nausea and vomiting induced by irritant 
effects on the intestinal mucosa, following oral administration. Furthermore, the higher doses 
required for tissue amoebicidal activity showed cardiotoxic effects in a proportion of the 
patients treated [25]. The concentration dependent negative inotropic and chronotropic effects 
are thought to be mediated via the blocking of L-type calcium channels in the heart [26]. 
Although ECG changes including T-wave inversion and prolongation of the Q-T interval are 
reported at higher dose ranges (total dose > 1gm), cardiovascular function usually returns to 
normal [27]. Unfortunately, while the cardiotoxicity studies on emetine define the side effects 
in relation to the administered dose, very little is known regarding the plasma concentrations 
after therapeutic administration or indeed the proportion of drug bound to plasma proteins. 
Studies in rats and dogs have shown tissue concentrations in the liver and kidney to be higher 
than in plasma. However, significant species and strain-specific variability in the 
susceptibility of experimental animals to emetine toxicity preclude the extrapolation of these 
findings to humans [27]. 
A synthetic modification of the drug, dehydroemetine (Roche), which structurally differs 
from the dihydroemetine hydrate only in a double bond next to the ethyl substituent, is 
reported to retain its anti-amoebicidal properties while producing fewer side effects [28]. This 
development achieved a major breakthrough in the treatment of amoebiasis with seven-day 
treatment regimes (1 mg/kg body weight) resulting in fewer side effects due to reduced 
accumulation in tissues [28,29]. Early radio tracer studies by Schwartz in 1965 comparing 
excretion of emetine dihydrochloride and dehydroemetine reported 67% and 91% clearance 
respectively, 3 days after treatment, possibly explaining the reduced side effects of the latter 
[30]. The replacement of emetine with the much safer metronidazole meant that further 
research into the drug was not actively pursued. More recent work comparing in vitro data on 
emetine for Entamoeba species report IC50 values ranging from 26 to 60 µM [30]. In contrast, 
the in vitro IC50 data reported for malaria ranges from 5–50 nM, making an objective 
argument for the further investigation of emetine as a repositioned drug in malaria. 
To permit further dose reductions in the drug, we further investigated the role of emetine 
dihydrochloride hydrate as a candidate for artemisinin combination therapy. Data from 
preliminary drug interaction studies of emetine dihydrochloride hydrate and DHA show the 
effect to range from additive to mildly antagonistic depending on the dose ratios used. While 
the FIC50 isobolograms show an antagonistic trend, the FIC90 isobolograms follow an 
additive trend. The sum 50% and 90% fractional inhibitory concentration (∑FIC 50. 90) of the 
interaction of emetine dihydrochloride hydrate and DHA against the K1 strain of P. 
falciparum ranged from 0.88-1.48. ∑FIC values predict the drug ratios to fall mainly within 
the additive range when applying criteria used by Bhattacharya et al. (i.e. ∑FIC < 1 
synergism, ∑FIC ≥ 1 and < 2 additive, interaction, ∑FIC ≥ 2 and < 4 slight antagonism, ∑FIC 
≥ 4 marked antagonism). When the more stringent criteria used by Abiodun et al. [31], are 
applied (i.e. ∑FIC < 0.8 = synergism, ∑FIC ≥ 0.8-1.4 = additive, ∑FIC ≥ 1.4 = antagonistic) 
the drug ratios fall within the additive to mildly antagonistic range. Vivas et al. [32] interpret 
interactivity as ∑FIC cut off values for synergy or antagonism being < or > 1 respectively, 
with ‘additivity’ defined as ∑FICs = 1. However, the very narrow definition of ‘additivity’ 
here could result in the exclusion of potentially effective compounds combination with very 
few hits identified in this category. 
Assessing in vitro interactions between anti-malarials has gained increased significance with 
increasing evidence of combination therapies postponing resistance [18]. The widely used 
checkerboard and fixed-drug ratio methods are reliant on the predetermination of IC50 values 
of the component drugs [32-34]. The latter has advantages over the former because the dose 
response curves depend on drug concentration ratios calculated on the basis of 100-0% 
parasite inhibition which permits a more rigorous and accurate calculation of regression curve 
fit and IC50 values. Variations in FIC cut off values proposed in published literature however, 
provide very little guidance on standardized interpretations for these parameters. A review of 
the current literature on interpretation of drug interaction data highlights many pitfalls and 
inaccuracies [35,36]. For diseases like malaria, combinatorial drug regimes will ensure 
delaying the onset of resistance and the search for suitable partner drugs will be a high 
priority. Hence, the surprising lack of consensus and standardized methods for interpreting 
drug interaction data is rather disconcerting. Furthermore, simplistic mechanistic deductions 
based on parasite clearance may result in overlooking important candidates merely because 
they are judged mildly antagonistic using current methods which define synergy based on 
combined anti-parasitic potency being higher than the individual potencies added together. 
Data from preliminary stage-specific experiments where the drug was added to synchronized 
cultures in the trophozoite phase, show distinct differences in the progression of the life cycle 
through 24, 48 and 72 h (Figure 7). The inevitable advantages afforded by a two pronged 
attack in delaying the onset of resistance and perhaps reducing therapeutic doses of individual 
drugs and hence their side effects, may need to be considered in an objective manner prior to 
simplistically labelling candidates as antagonistic, additive or synergistic. 
The most successful anti-malarials to date have indeed been plant derived molecules 
(quinolones/artemisinins). In emetine, yet another opportunity is presented to investigate a 
natural product which has been already been shown to be amenable to chemical modification 
and toxicity reduction. Malaria is a deadly disease with a complex clinical presentation. The 
hepatic concentration of emetine could be potentially exploited to address the lack of 
treatment options to destroy the dormant liver stages of the parasite. Its nanomolar anti-
malarial efficacy makes it a useful reserve treatment option for cerebral malaria where in-
hospital patient monitoring is routine. Since most of the pharmacokinetic published work on 
emetine was carried out in the 1960’s, reliable quantitative data on serum/tissue levels are 
lacking. Revisiting this area of research with the benefit of current post-genomic technologies 
would enable the quantitative definition of these parameters and perhaps permit the safe use 
of the drug within narrow therapeutic windows. 
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